小剂量利妥昔单抗联合静脉注射免疫球蛋白成功治疗难治性红皮病性天疱疮。

IF 5.4 3区医学 Q2 CELL BIOLOGY

Inflammation Research Pub Date : 2025-06-03 DOI:10.1007/s00011-025-02059-8

Jiawen Zhang, Chengfeng Zhang, Zhongyi Xu, Jun Liang, Qinyuan Zhu

{"title":"小剂量利妥昔单抗联合静脉注射免疫球蛋白成功治疗难治性红皮病性天疱疮。","authors":"Jiawen Zhang, Chengfeng Zhang, Zhongyi Xu, Jun Liang, Qinyuan Zhu","doi":"10.1007/s00011-025-02059-8","DOIUrl":null,"url":null,"abstract":"Background: Erythrodermic pemphigus foliaceus (EPF) is a severe, often refractory autoimmune disease.Method: We report successful treatment of refractory EPF in a 59-year-old male using low-dose rituximab (RTX) and intravenous immunoglobulin (IVIG).Results: Initial high-dose corticosteroids and IVIG failed, complicated by infections. A modified regimen of RTX (0.5 g) and IVIG (0.4 g/kg/day for three days) every two weeks for two cycles induced remission, with a mild relapse at six months successfully retreated. No infections occurred during 15-month follow-up.Conclusion: This combined therapy using low-dose RTX and IVIG may be a safe and effective option for refractory EPF, potentially minimizing infection risk associated with standard RTX dosing. Further studies are warranted.","PeriodicalId":13550,"journal":{"name":"Inflammation Research","volume":"74 1","pages":"89"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin.\",\"authors\":\"Jiawen Zhang, Chengfeng Zhang, Zhongyi Xu, Jun Liang, Qinyuan Zhu\",\"doi\":\"10.1007/s00011-025-02059-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Erythrodermic pemphigus foliaceus (EPF) is a severe, often refractory autoimmune disease.Method: We report successful treatment of refractory EPF in a 59-year-old male using low-dose rituximab (RTX) and intravenous immunoglobulin (IVIG).Results: Initial high-dose corticosteroids and IVIG failed, complicated by infections. A modified regimen of RTX (0.5 g) and IVIG (0.4 g/kg/day for three days) every two weeks for two cycles induced remission, with a mild relapse at six months successfully retreated. No infections occurred during 15-month follow-up.Conclusion: This combined therapy using low-dose RTX and IVIG may be a safe and effective option for refractory EPF, potentially minimizing infection risk associated with standard RTX dosing. Further studies are warranted.\",\"PeriodicalId\":13550,\"journal\":{\"name\":\"Inflammation Research\",\"volume\":\"74 1\",\"pages\":\"89\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammation Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00011-025-02059-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00011-025-02059-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：红皮病性叶状天疱疮（EPF）是一种严重的难治性自身免疫性疾病。方法：我们报告使用低剂量利妥昔单抗（RTX）和静脉注射免疫球蛋白（IVIG）成功治疗难治性EPF的59岁男性。结果：初始大剂量皮质类固醇和IVIG治疗失败，并发感染。RTX （0.5 g）和IVIG （0.4 g/kg/天，3天）的改良方案每两周进行两个周期诱导缓解，6个月时轻度复发成功消退。随访15个月无感染发生。结论：使用低剂量RTX和IVIG联合治疗难治性EPF可能是一种安全有效的选择，潜在地降低了与标准RTX剂量相关的感染风险。进一步的研究是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin.

Background: Erythrodermic pemphigus foliaceus (EPF) is a severe, often refractory autoimmune disease.

Method: We report successful treatment of refractory EPF in a 59-year-old male using low-dose rituximab (RTX) and intravenous immunoglobulin (IVIG).

Results: Initial high-dose corticosteroids and IVIG failed, complicated by infections. A modified regimen of RTX (0.5 g) and IVIG (0.4 g/kg/day for three days) every two weeks for two cycles induced remission, with a mild relapse at six months successfully retreated. No infections occurred during 15-month follow-up.

Conclusion: This combined therapy using low-dose RTX and IVIG may be a safe and effective option for refractory EPF, potentially minimizing infection risk associated with standard RTX dosing. Further studies are warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammation Research 医学-免疫学

CiteScore

9.90

自引率

1.50%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Inflammation Research (IR) publishes peer-reviewed papers on all aspects of inflammation and related fields including histopathology, immunological mechanisms, gene expression, mediators, experimental models, clinical investigations and the effect of drugs. Related fields are broadly defined and include for instance, allergy and asthma, shock, pain, joint damage, skin disease as well as clinical trials of relevant drugs.